Artelo Biosciences, Inc.

Artelo Biosciences, Inc.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company, not a family office or asset manager. The firm's core business involves developing proprietary cannabinoid-derived drug candidates, such as ART27.13, a GPR119 agonist for appetite stimulation. Its pipeline also includes preclinical programs targeting various disease states. The company operates as a publicly traded entity, funding its research and development through equity offerings and partnerships. It has not disclosed any investment strategy typical of asset managers, nor does it publicly report AUM or deployment figures. Its focus remains on advancing its drug candidates through clinical trials and regulatory processes. Artelo's team size, headquarters location, and founding year are not established in public sources. The firm does not maintain a disclosed website, LinkedIn presence, or other easily accessible professional profiles. This absence of data renders the firm effectively opaque to external analysis. Structurally, Artelo Biosciences is a Delaware corporation trading on the OTC market, distinct from the family-office or investment-firm models typically profiled. Its sole function is drug development, not capital management. Without public filings or corporate communications, further structural classification is not possible.